August 30, 2010
Bharatbook added a new report on “Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020” which gives a comprehensive analysis of M&A for the pharmaceutical sector.
Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020
how will M&A affect the pharma industry this decade?
Last year was important for pharmaceutical mergers and acquisitions, with total deal values in 2009 reaching almost $150bn. Driving this activity were three ‘mega-mergers’ at the heart of the industry, as Pfizer took over Wyeth, Roche bought the remaining shares in Genentech, and Merck & Co acquired Schering-Plough. Those historic deals signal the continued importance of mergers and acquisitions (M&A) as a strategy among pharma companies, with associated benefits and challenges. The importance of consolidation and alliances will increase from 2010 onwards, as companies adapt to changing conditions within the industry and market. Companies will turn to M&A to consolidate their businesses and to diversify into other developmental areas, our new study discusses. How will recent M&A activity work out for the companies involved? Also, where will important M&A activities be most likely to occur during the remainder of this decade, and what will their prospects be? Our new report tackles questions such as those, providing analysis to aid your decision making and save you time.( http://www.bharatbook.com/detail.asp?id=149099&rt=Prospects-for-Pharma-Mergers-Acquisitions-and-Alliances-2010-2020.html )
Our report – Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020 – reviews the recent M&A history of the industry and determines which companies will be most likely to perform M&A, and which companies are most likely to be targeted. Our research shows that M&A activity will be important to the pharmaceutical industry from 2010 to 2020, with opportunities and challenges arising. Many companies will turn to mergers, acquisitions or alliances. But which deals will leave companies well placed to survive the patent cliff, consolidate operations and expand revenues? Our latest study tackles those questions.
Our study also reviews prominent companies operating in the pharma biotech sector, where big pharma companies will seek to expand their operations this decade. We assess R&D pipelines and existing products that have the potential to make a significant market impact. Our study covers the incentives to seek M&A deals and the difficulties that can arise from those transactions. In particular, our new report provides an overview of the options for companies seeking to increase R&D and commercial presence in the industry’s growth areas.
Comprehensive analysis of M&A for the pharmaceutical sector
Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020 critically examines that aspect of the pharmaceutical industry through a review of primary and secondary information sources. Our study provides revenue forecasts, market share analyses, discussions of products and strategies, as well as analyses of commercial drivers and restraints.
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149099&rt=Prospects-for-Pharma-Mergers-Acquisitions-and-Alliances-2010-2020.html
Pharmaceutical Mergers and Acquisitions
STRATEGIC INSIGHTS: mergers, acquisitions & investments in the natural personal care industry
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com